Studying How Electronic Monitoring Affects Patient Treatment Compliance in Blood Cancers Using Oral Therapies

What this Trial Is About

Researchers are studying patients with hemopathies who are starting oral therapy treatments to better understand how electronic monitoring might improve treatment adherence and safety. The study compares standard follow-up care with follow-up using a digital telemonitoring platform called Cureety, designed to help cancer patients report side effects and support medical teams. This research focuses on patients taking oral therapies for six months or more and aims to detect and manage side effects in real time to improve patient safety and quality of life. Participants will be randomly assigned to one of two groups one receiving standard care and the other using the Cureety telemonitoring platform. The platform allows patients to self-report adverse events, which helps healthcare providers monitor treatment effects more closely. Both groups may receive intravenous treatments alongside oral therapy when recommended. The study will last at least six months for each participant, focusing on treatment adherence and safety. During the study, participants will be regularly assessed for medication compliance at months 1, 3, and 6. Researchers will monitor adverse events continuously or at specified times and track unexpected hospitalizations, including their number, duration, and reasons over six months. Patients will be supported to follow prescribed treatments correctly, and the study will evaluate how electronic monitoring affects treatment adherence and patient health outcomes over time.

Evaluation of the Impact of Electronic Monitoring on Patient Compliance in Hematology